ATE268599T1 - Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn - Google Patents

Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn

Info

Publication number
ATE268599T1
ATE268599T1 AT00958596T AT00958596T ATE268599T1 AT E268599 T1 ATE268599 T1 AT E268599T1 AT 00958596 T AT00958596 T AT 00958596T AT 00958596 T AT00958596 T AT 00958596T AT E268599 T1 ATE268599 T1 AT E268599T1
Authority
AT
Austria
Prior art keywords
beta
release
derivatives
naphtaquinone
glutamat
Prior art date
Application number
AT00958596T
Other languages
English (en)
Inventor
Maurice Israel
Jordi Molgo
Christian Bloy
Cesar Mattei
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE268599T1 publication Critical patent/ATE268599T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00958596T 1999-07-21 2000-07-21 Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn ATE268599T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9909469A FR2796552A1 (fr) 1999-07-21 1999-07-21 Nouvelle utilisation de derives de la beta-naphtoquinone et de leurs sels pour la fabrication de medicaments exercant un effet inhibiteur sur la liberation de glutamate dans le cerveau
PCT/FR2000/002120 WO2001005404A1 (fr) 1999-07-21 2000-07-21 Utilisation de derives de la beta-naphtoquinone pour la fabrication de medicaments exerçant un effet inhibiteur sur la liberation de glutamate par le cerveau
CA2368850A CA2368850C (en) 1999-07-21 2002-01-22 Methods for the prevention and/or the treatment of glutamate cytotoxicity

Publications (1)

Publication Number Publication Date
ATE268599T1 true ATE268599T1 (de) 2004-06-15

Family

ID=32178092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00958596T ATE268599T1 (de) 1999-07-21 2000-07-21 Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn

Country Status (10)

Country Link
US (4) US7572774B2 (de)
EP (1) EP1196176B1 (de)
AT (1) ATE268599T1 (de)
CA (1) CA2368850C (de)
DE (1) DE60008111T2 (de)
DK (1) DK1196176T5 (de)
ES (1) ES2215716T3 (de)
FR (1) FR2796552A1 (de)
PT (1) PT1196176E (de)
WO (1) WO2001005404A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027325A1 (en) * 1993-05-07 1994-11-24 Vlsi Technology, Inc. Integrated circuit structure and method
EP1961738A1 (de) * 2007-02-15 2008-08-27 Faust Pharmaceuticals Neue Verbindungen mit glutamatantagonistischen Eigenschaften und deren Verwendung
BR112018012214A2 (pt) 2015-12-16 2018-11-27 Clevexel Pharma composição farmacêutica de liberação bipulsátil e seu uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130515A (ja) * 1983-12-15 1985-07-12 Shiratori Seiyaku Kk 血中２，３−ジホスホグリセリン酸上昇剤
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
GB9100028D0 (en) * 1991-01-02 1991-02-20 Ici Plc Compounds
FR2707495B1 (fr) * 1993-07-02 1995-09-01 Roussel Uclaf Nouvelle utilisation de dérivés de la béta-naphtoquinone ainsi que de leurs sels.
BE1011151A3 (fr) * 1997-05-13 1999-05-04 Jose Remacle Utilisation d'une composition pharmaceutique dans le traitement et/ou la prevention de l'ischemie.
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels

Also Published As

Publication number Publication date
DK1196176T3 (da) 2004-06-14
FR2796552A1 (fr) 2001-01-26
US20020115617A1 (en) 2002-08-22
DE60008111D1 (de) 2004-03-11
US7572774B2 (en) 2009-08-11
PT1196176E (pt) 2004-08-31
ES2215716T3 (es) 2004-10-16
WO2001005404A1 (fr) 2001-01-25
DE60008111T2 (de) 2004-12-02
CA2368850A1 (en) 2003-07-22
EP1196176A1 (de) 2002-04-17
EP1196176B1 (de) 2004-06-09
US20070225235A1 (en) 2007-09-27
US20070225237A1 (en) 2007-09-27
CA2368850C (en) 2010-12-07
DK1196176T5 (da) 2004-07-12
US20070225236A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
ATE533484T1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
DE69706566D1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
IL111078A0 (en) Inhibitors of beta-amyloid protein production
ATE332702T1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
ATE212223T1 (de) Verwendung von sertraline zur herstellung eines arzneimittels zur behandlung von obsessiv- kompulsiven erkrankungen
ATE214287T1 (de) Verwendung von relaxin zur herstellung eines arzneimittels für die behandlung kardiovaskulären krankeiten.
ATE253932T1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
DE69923998D1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE69921662D1 (de) Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose
ATE288761T1 (de) Verwendung von glykosaminoglykane zur behandlung seniler demenz
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
ATE268599T1 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn
ATE350027T1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können
DE50007381D1 (de) Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
DE69701258D1 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
UEP Publication of translation of european patent specification

Ref document number: 1196176

Country of ref document: EP